Spark Therapeutics Inc to Post Q2 2019 Earnings of ($1.28) Per Share, SunTrust Banks Forecasts (NASDAQ:ONCE)

Share on StockTwits

Spark Therapeutics Inc (NASDAQ:ONCE) – Stock analysts at SunTrust Banks issued their Q2 2019 earnings estimates for Spark Therapeutics in a report issued on Wednesday, June 19th. SunTrust Banks analyst J. Lee anticipates that the biotechnology company will post earnings per share of ($1.28) for the quarter. SunTrust Banks also issued estimates for Spark Therapeutics’ Q3 2019 earnings at ($1.17) EPS, Q4 2019 earnings at ($1.13) EPS, FY2019 earnings at ($4.29) EPS, FY2020 earnings at ($4.22) EPS, FY2021 earnings at ($3.80) EPS, FY2022 earnings at ($3.09) EPS and FY2023 earnings at ($1.96) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.33). Spark Therapeutics had a negative return on equity of 16.68% and a negative net margin of 124.33%. The business had revenue of $20.77 million for the quarter, compared to the consensus estimate of $31.20 million.

ONCE has been the topic of several other reports. Stifel Nicolaus cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating and boosted their price target for the stock from $65.00 to $114.50 in a research report on Wednesday, February 27th. BMO Capital Markets boosted their price target on shares of Spark Therapeutics from $46.00 to $114.50 and gave the stock a “market perform” rating in a research report on Tuesday, February 26th. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 25th. Barclays cut shares of Spark Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $74.00 to $115.00 in a research report on Monday, March 25th. Finally, William Blair began coverage on shares of Spark Therapeutics in a research report on Tuesday, February 26th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, seventeen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $78.45.

Shares of NASDAQ:ONCE opened at $100.79 on Monday. The business’s 50-day simple moving average is $106.64. The company has a quick ratio of 5.59, a current ratio of 5.94 and a debt-to-equity ratio of 0.18. Spark Therapeutics has a one year low of $34.53 and a one year high of $114.20. The company has a market cap of $3.87 billion, a PE ratio of -47.77 and a beta of 2.28.

A number of large investors have recently modified their holdings of the stock. Bank of Montreal Can grew its holdings in Spark Therapeutics by 84.8% in the fourth quarter. Bank of Montreal Can now owns 6,011 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 2,758 shares during the last quarter. Rhumbline Advisers grew its holdings in Spark Therapeutics by 47.7% in the fourth quarter. Rhumbline Advisers now owns 42,372 shares of the biotechnology company’s stock valued at $1,658,000 after purchasing an additional 13,686 shares during the last quarter. SG Americas Securities LLC grew its holdings in Spark Therapeutics by 7.0% in the fourth quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 313 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Spark Therapeutics by 3.2% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,696 shares of the biotechnology company’s stock valued at $693,000 after purchasing an additional 546 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Spark Therapeutics by 103.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,718 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 1,890 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Recommended Story: How to start trading in the forex market?

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SSE PLC/S  Receives Consensus Rating of “Hold” from Brokerages
SSE PLC/S Receives Consensus Rating of “Hold” from Brokerages
Zacks: Analysts Expect 3D Systems Co.  to Announce -$0.04 Earnings Per Share
Zacks: Analysts Expect 3D Systems Co. to Announce -$0.04 Earnings Per Share
James Hardie Industries plc  Receives Consensus Rating of “Hold” from Brokerages
James Hardie Industries plc Receives Consensus Rating of “Hold” from Brokerages
Zacks: Brokerages Anticipate CenterPoint Energy, Inc.  to Announce $0.33 EPS
Zacks: Brokerages Anticipate CenterPoint Energy, Inc. to Announce $0.33 EPS
Zacks: Brokerages Anticipate Community Health Systems  to Announce -$0.49 Earnings Per Share
Zacks: Brokerages Anticipate Community Health Systems to Announce -$0.49 Earnings Per Share
SYSCO Co.  Sees Significant Decrease in Short Interest
SYSCO Co. Sees Significant Decrease in Short Interest


 
© 2006-2019 Zolmax.